Expand PBM Menu
PBM MENU

PBM Latest Press Releases

-- May 15, 2026 --

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing Globe Newswire 9:15 AM

-- April 23, 2026 --

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder Globe Newswire 7:00 AM

-- April 20, 2026 --

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source Globe Newswire 7:42 AM

-- April 17, 2026 --

Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine Globe Newswire 9:15 AM

-- April 8, 2026 --

Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5-Supported Clinical Activities Globe Newswire 9:15 AM

-- March 11, 2026 --

Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone Globe Newswire 9:15 AM

-- March 3, 2026 --

Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial Globe Newswire 9:15 AM

-- February 20, 2026 --

Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment Globe Newswire 5:20 PM

-- February 17, 2026 --

Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders Globe Newswire 9:15 AM

-- February 13, 2026 --

Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway Globe Newswire 6:30 PM

-- February 11, 2026 --

Psyence BioMed Announces Settlement of Shareholder Litigation Globe Newswire 9:15 AM

-- January 28, 2026 --

Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split Globe Newswire 6:30 PM
Market Data Delayed 15 Minutes